Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Pindac
Synonyms :
pinacidil
Class :
Antihypertensive
Dosage Forms & StrengthsÂ
Intravenous solutionÂ
0.2mg/kgÂ
Hypertension (Off-label)Â
Administer 0.2 mg/kg intravenously as a single doseÂ
Dosage Forms & StrengthsÂ
Safety and efficacy are not establishedÂ
Refer adult dosingÂ
spironolactone and hydrochlorothiazide
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
spironolactone and hydrochlorothiazide
may increase the hyperkalemic effect of potassium salts
may increase the hyperkalemic effect of potassium salts
may increase the hyperkalemic effect of potassium salts
may increase the hyperkalemic effect of potassium salts
may increase the hyperkalemic effect of potassium salts
may increase the hyperkalemic effect of potassium salts
may increase the hyperkalemic effect of potassium salts
It may enhance the serum concentration when combined with CYP3A4 Substrates
may have an increased hyperkalemic effect when combined with angiotensin II receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin II receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin II receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin II receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin II receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with potassium salts
may have an increased hyperkalemic effect when combined with potassium salts
may have an increased hyperkalemic effect when combined with potassium salts
may have an increased hyperkalemic effect when combined with potassium salts
may have an increased hyperkalemic effect when combined with potassium salts
may have an increased hyperkalemic effect when combined with potassium salts
may have an increased hyperkalemic effect when combined with potassium salts
may have an increased hyperkalemic effect when combined with potassium salts
Frequency not definedÂ
PalpitationsÂ
DizzinessÂ
HeadacheÂ
TachycardiaÂ
Black box warning:Â
NoneÂ
Contraindications/caution:Â
Contraindications:Â
Caution:Â
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
pinacidil is a vasodilator medication that belongs to the class of drugs known as potassium channel openers. Its pharmacological effects are primarily related to its ability to open ATP-sensitive potassium channels (KATP channels) in various tissues, especially in vascular smooth muscle cells. Â
Pharmacokinetics:Â
AbsorptionÂ
pinacidil is typically administered orally. It is well-absorbed from the gastrointestinal tract after oral administration. pinacidil undergoes extensive first-pass metabolism in the liver before reaching the systemic circulation.Â
DistributionÂ
pinacidil and its metabolites bind to plasma proteins to some extent. The drug and its metabolites are distributed to various tissues, including vascular smooth muscle cells and the liver.Â
MetabolismÂ
pinacidil undergoes extensive metabolism in the liver. The primary metabolites of pinacidil include pinacidil and the corresponding glucuronide conjugates. The metabolism of pinacidil involves cytochrome P450 enzymes, particularly CYP3A4.Â
Elimination and ExcretionÂ
The metabolites of pinacidil are primarily excreted in the urine. Renal excretion is an important route for the elimination of pinacidil and its metabolites from the body. The elimination half-life of pinacidil is approximately 2 to 4 hours.
Administration:Â
Oral administrationÂ
It is typically administered orally in the form of tablets.Â
Patient information leafletÂ
Generic Name: pinacidilÂ
Why do we use pinacidil?Â
pinacidil is a medication primarily used in the treatment of hypertension and angina pectoris. It belongs to the class of drugs known as potassium channel openers and has vasodilatory effects, meaning it widens blood vessels. Â